Figure 3.
Cytoplasmic SPARC expression as a potential negative predictive biomarker for overall survival (A and C) and progression-free survival (B and D) in gemcitabine-treated aPDAC patients. Univariate analysis (Kaplan–Meier curves and log-rank tests) of cytoplasmic SPARC expression in the tumour tissue of (A and B) gemcitabine-based treated aPDAC pts and (C and D) fluoropyrimidine-based treated aPDAC pts. Crossed lines indicate censored cases.